Lorediplon
CAS: 917393-39-6
Rif. 3D-SLB39339
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione | ||
| 100mg | Fuori produzione |
Informazioni sul prodotto
- Acetamide, N-[2-fluoro-5-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methyl-
- N-[2-Fluoro-5-[3-(2-thienylcarbonyl)pyrazolo[1,5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide
Lorediplon is a novel sedative with a profile that is characterized by a rapid onset and short duration of action. Lorediplon binds selectively to the α1 subunit of the L-type voltage-gated calcium channel (L-VGCC) and blocks calcium influx into cells. It has been shown to be safe in clinical studies involving healthy volunteers, as well as patients with insomnia or depression. Lorediplon has also been evaluated in clinical trials for use as a diagnostic agent for Parkinson's disease, Alzheimer's disease, and dementia. These studies showed that lorediplon is able to cross the blood brain barrier, bind to neurons in the brain, and improve sleep quality, mood, and memory when used at low doses. Lorediplon is an innovative drug because it has not yet been approved for any therapeutic indication but has demonstrated efficacy in early clinical trials for several diseases. The mechanism of lorediplon may be related to its ability to inhibit excit
